Singapore: +65-31631880 | India: +91-40-42023318
  U.S / Canada Toll Free: +1-866-259-4781
  Kenya: +254-732-300719


Clinical Trial News

Researchers awarded £3.5m grant to improve prevention of tuberculosis (TB) in South African schoolchildren

The Medical Research Council (MRC) has awarded a grant of £3.5m to researchers from Queen Mary University of London (QMUL) and University of Cape Town (UCT) to carry out a trial to determine...

New compound found to cure Ebola in monkeys

Researchers from the US have collaborated on a treatment for Ebola with 100% success in curing primate monkeys, offering hope that a therapy will be developed in the near future.

Stem cell study to help fight brittle-bone disease

A study involving researchers from the Department of Genetics at the University of Leicester is to be conducted for the first time involving the transplantation of stem cells into foetuses with the...

Cancer Research UK launches £100m grand challenges to tackle the most important questions in cancer

Cancer Research UK has today (Monday) launched Grand Challenges* - the biggest and most ambitious cancer grants in the world - which aim to overcome the greatest barriers standing in the way of...

Investigational biologic cleared skin better, faster and for longer than ustekinumab in Phase II psoriasis study

New results from a Phase II head-to-head psoriasis study showed superior efficacy of Boehringer Ingelheim's investigational biologic compound BI 655066*, over ustekinumab.

Long-term efficacy of Gilenya reinforced by new 'no evidence of disease activity' (NEDA-4) analysis in MS patients over seven years

Novartis has announced a new analysis from the phase III FREEDOMS and FREEDOMS II trials reinforcing the long-term efficacy profile of Gilenya® (fingolimod).

New data presented from large studies consolidating the effectiveness, safety and tolerability of Sativex in patients with spasticity symptoms in MS

Almirall, the global pharmaceutical company based in Barcelona, presented new clinical evidences of Sativex®, the only medicine derived from cannabinoids to treat spasticity symptoms in MS...

Bavarian Nordic announces initiation of safety and immunogenicity study of Ebola vaccine regimen in Sierra Leone

Bavarian Nordic A/S has announced the initiation of a new clinical study of the Ebola prime-boost vaccine regimen that combines Bavarian Nordic's MVA-BN® Filo vaccine with the Ad26.

James Lind Institute Newsletter
James Lind Institute Linkedin
James Lind Institute RSS
James Lind Institute Email Update
James Lind Institute Blog
James Lind Institute Facebook